Could tailored steroids save more lives in severe pneumonia?
NCT ID NCT07357935
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving steroids based on a patient's immune status can reduce deaths in severe pneumonia with respiratory failure. About 500 ICU patients will receive methylprednisolone, with doses adjusted according to their inflammatory profile. The goal is to find out who benefits most from this treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Methylprednisolone (a steroid drug)
- What this could lead to
- If successful, this could show that personalized steroid dosing improves survival in severe pneumonia patients.
- What could go wrong
- This is an early-phase study (Phase 1/2) with 500 participants, so results may not apply broadly. Steroids also carry risks like infections and high blood sugar.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple inhaled combo keep pneumonia patients off ventilators?
- Flu vaccine showdown: which shot protects seniors best?
- Can a Diaphragm-Sensing ventilator mode reduce breathing asynchrony?
- Can inhaled nitric oxide speed pneumonia recovery?
- Pneumonia culprit may be rarer than doctors think
- Which oxygen strategy saves more lives? large trial puts three methods to the test